Anger and Psychotrauma: Data From Military and Civilians (COPMiCiv)

April 27, 2023 updated by: Direction Centrale du Service de Santé des Armées

Post-Traumatic Stress Disorder (PTSD) is mainly associated with several emotions such as anger, guilt or shame. By interfering with psychotherapeutic work these emotions can be problematic. When suffering from PTSD, pervasive anger can also have relational consequences. Anger and PTSD are mutually reinforcing: anger can aggravate PTSD symptoms and aggressive behaviours, and conversely, PTSD promotes high levels of anger and aggression. A few explanatory hypotheses have been proposed. In terms of personality factors, anger-treatment may promote the severity of PTSD symptoms and the development of aggressive behaviours. In terms of stressors, exposure to combat and combat-related moral harms could play a role in the relationship between PTSD, anger and traumatic experiences over the course of life. Finally, in clinical terms, in the presence of PTSD, anger and aggressive behaviours may be triggered by substance abuse and depression.

Within the Anglo-Saxon literature, it is recognized that both civilians and military personnel with PTSD exhibit high levels of anger, with a possible predominance among military personnel. While we know that anger management mechanisms can be strongly influenced by cultural aspects and the type of event, there is no data in the French population.

This study proposes to fill in our knowledge of anger-PSTD relationships in the French population and by comparing civilian and military population.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Arras, France, 62000
      • Lille, France, 59001
      • Lille, France, 59000
      • Lormont, France, 33310
      • Nice, France, 06001
        • Recruiting
        • Chu de Nice
        • Contact:
      • Nice, France, 06200
      • Thuir, France, 66301
        • Not yet recruiting
        • Centre Hospitalier Léon-Jean Grégory de Thuir
        • Contact:
      • Villejuif, France, 94806
        • Not yet recruiting
        • Groupe Hospitalier Paul Guiraud
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study population will be composed of participants suffering from PTSD, half of which will have civilian status and the other half a military status.

Description

Inclusion Criteria:

  • To have a PTSD diagnosis
  • To be at least 18 years of age

Exclusion Criteria:

  • To suffer from trauma-related physical condition (including Traumatic Brain Injury)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Civilian group
Participants with civilian status
Behavioral: Structured clinical interview
A structured clinical interview will be performed at enrollment.
Behavioral: Psychological questionnaires
Several psychological questionnaires will be performed at enrollment.
Military group
Participants with military status
Behavioral: Structured clinical interview
A structured clinical interview will be performed at enrollment.
Behavioral: Psychological questionnaires
Several psychological questionnaires will be performed at enrollment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety score
Time Frame: At enrollment
Spielberger's State-Trait Anger Expression Inventory-II (STAXI-II) will be used to assess anxiety
At enrollment
PTSD severity score
Time Frame: At enrollment
Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS-5) will be used to assess PTSD severity score. CAPS-5 score may range from 0 to 120 with higher scores meaning greater PTSD severity.
At enrollment
Number of life traumatic events
Time Frame: At enrollment
Life Event Checklist (LEC) will be used to assess the number of traumatic events experienced by participants throughout their lifetime
At enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aggressivity score
Time Frame: At enrollment
Aggressivity Questionnaire (AQ12) will be used to assess aggressivity score. AQ12 score may range from 6 to 72 with higher scores meaning higher aggressivity levels.
At enrollment
Anger Rumination score
Time Frame: At enrollment
Anger Rumination Scale (ARS) will be used to assess anger rumination score. ARS score may range from 19 to 76 with higher scores corresponding to greater levels of anger rumination.
At enrollment
Alcohol consumption score
Time Frame: At enrollment
Alcohol Use Identification Test (A.U.D.I.T.) will be used to assess alcohol consumption score Score ≥ 5: at risk use; Score ≥ 8 (7 in women): harmful use; Score ≥ 12 (11 in women): likely alcohol dependence
At enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Direction Centrale du Service de Santé des Armées

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 21, 2020

Primary Completion (Anticipated)

September 1, 2024

Study Completion (Anticipated)

September 1, 2024

Study Registration Dates

First Submitted

August 15, 2020

First Submitted That Met QC Criteria

August 15, 2020

First Posted (Actual)

August 19, 2020

Study Record Updates

Last Update Posted (Actual)

April 28, 2023

Last Update Submitted That Met QC Criteria

April 27, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019PPRC16
  • 2020-A00507-32 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-traumatic Stress Disorder

Clinical Trials on Structured clinical interview

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe